Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Open access
Jiang, Xiaofeng, Zhou, Jun, Giobbie-Hurder, Anita, Wargo, Jennifer, Hodi, F. Stephen · 2013 · Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops. Interest remains in combining targeted and immune therapies to overcome resistance and improve durability of clinical benefit. One mechanism of evading immune destruction is programmed death-1-ligand 1 (PD-L1) expression by tumors that results in potent antitumor immune suppression. Experimental Design: BRAFi-resistant melanoma cells were examined for changes in PD-L1 expression by immunoblot and flow cytometry. Signaling pathways involved in altering PD-L1 expression were examined. Strategies to maximize the effect of the BRAFi therapy were studied including MEKi, MEKi combinations, and additional pathways including phosphoinositide-3 kinase (PI3K). Results: Melanoma cells resistant to BRAFi exhibit increased MAPK signaling and promotion of PD-L1 expression. PD-L1 expression is transcriptionally modulated by c-Jun and augmented by STAT3. MEK inhibition (MEKi) regains downregulation of MAPK signaling and suppresses the production of PD-L1. MEKi in melanoma cells shows dual therapeutic effects with simultaneous suppression of PD-L1 expression and induction of apoptosis. By combining MEKi with BRAFi, an additive effect on the inhibition of PD-L1 expression results. Conclusions: We report a novel mechanism that suppresses preexisting immune responses in patients with melanoma receiving BRAFi therapy. BRAFi resistance leads to increased expression of PD-L1 in melanoma cells, mediated by c-Jun and STAT3. MEKi may be feasible to counteract BRAFi resistance of MAPK reactivation and also for the additive effect of PD-L1 suppression. Potential therapeutic benefits of combining targeted inhibitors and immune modulation to improve patient outcomes should be investigated. Clin Cancer Res; 19(3); 598–609. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2731

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 516

Metadata

Authors
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S.
Affiliations
  • Harvard University (US)
  • Authors' Affiliations: 1Departments of Medical Oncology and 2Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School; 3Melanoma Disease Center, Dana-Farber/Brigham and Women's Cancer Center; 4Center for Immuno-oncology, Dana-Farber Cancer Institute; and 5Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Corresponding author
Hodi, F. Stephen
Venue
Clinical Cancer Research
Published
2013-01-31
Volume
19
Issue
3
Pages
598-609
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2089228335
Cited by
485
References
48
Citations by year
2026: 18 · 2025: 23 · 2024: 25 · 2023: 31 · 2022: 33 · 2021: 38 · 2020: 55 · 2019: 46 · 2018: 38 · 2017: 44 · 2016: 42 · 2015: 41 · 2014: 34 · 2013: 15
FWCI
11.82
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
melanoma, BRAF inhibitor resistance, MAPK signaling, PD-L1 expression, MEK inhibition, PI3K inhibition, c-Jun, STAT3, immune evasion, combination therapy, targeted therapy, apoptosis
MeSH terms
Enzyme Activation, Humans, Melanoma, Models, Biological, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-jun, Apoptosis, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, STAT3 Transcription Factor, TOR Serine-Threonine Kinases, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-2731
The paper
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013). The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-2731

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.